KRAS-MUTATED

Clinical trials for KRAS-MUTATED explained in plain language.

Never miss a new study

Get alerted when new KRAS-MUTATED trials appear

Sign up with your email to follow new studies for KRAS-MUTATED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New hope for KRAS lung cancer: drug duo targets tumors

Disease control Not yet recruiting

This study tests two drugs, luvometinib and anlotinib, together in people with advanced KRAS-mutated non-small cell lung cancer that has worsened after prior treatment. The goal is to see if the combination can shrink tumors. About 48 adults aged 18-75 will take part. This is not…

Matched conditions: KRAS-MUTATED

Phase: PHASE2 • Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. • Aim: Disease control

Last updated May 13, 2026 16:01 UTC

KRAS-MUTATED

Get alerted when new KRAS-MUTATED trials appear

New hope for KRAS lung cancer: drug duo targets tumors